Kanglong Huacheng and AstraZeneca China have reached a strategic cooperation. On May 20th, Kanglong Huacheng announced on its official WeChat account that it has reached a comprehensive strategic cooperation with AstraZeneca China on the integrated research and commercial production services, as well as innovative drug research and development, covering the entire process of drug discovery, preclinical and clinical development, including small molecule, large molecule, cell and gene therapy drugs. Kanglong Huacheng plans to invest an additional 91 million yuan in the Wuxi AstraZeneca Zhongjin Venture Capital Investment Fund in the near future. Both sides will fully leverage the resources and experience advantages of industry-leading medical and health fields, as well as the global entire industry chain, to support the growth of innovative medical enterprises.